BR0215029A - Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus - Google Patents

Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus

Info

Publication number
BR0215029A
BR0215029A BR0215029-8A BR0215029A BR0215029A BR 0215029 A BR0215029 A BR 0215029A BR 0215029 A BR0215029 A BR 0215029A BR 0215029 A BR0215029 A BR 0215029A
Authority
BR
Brazil
Prior art keywords
insulin molecule
preparing
diabetes mellitus
treating
composition
Prior art date
Application number
BR0215029-8A
Other languages
English (en)
Portuguese (pt)
Inventor
John Michael Beals
Michael Rosario Defelippis
Richard Dennis Dimarchi
Wayne David Kohn
Radmila Micanovic
Sharon Ruth Myers
Kingman Ng
Lianshan Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0215029A publication Critical patent/BR0215029A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR0215029-8A 2001-12-20 2002-12-12 Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus BR0215029A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34431001P 2001-12-20 2001-12-20
US41460402P 2002-09-27 2002-09-27
PCT/US2002/037601 WO2003053339A2 (en) 2001-12-20 2002-12-12 Insulin molecule having protracted time action

Publications (1)

Publication Number Publication Date
BR0215029A true BR0215029A (pt) 2005-12-20

Family

ID=26993857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215029-8A BR0215029A (pt) 2001-12-20 2002-12-12 Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus

Country Status (17)

Country Link
US (1) US20050014679A1 (https=)
EP (1) EP1545460A4 (https=)
JP (1) JP2005519041A (https=)
KR (1) KR20040070237A (https=)
AU (1) AU2002346490A1 (https=)
BR (1) BR0215029A (https=)
CA (1) CA2468100A1 (https=)
CO (1) CO5590884A2 (https=)
CZ (1) CZ2004710A3 (https=)
HR (1) HRP20040551A2 (https=)
HU (1) HUP0700126A2 (https=)
IL (1) IL161848A0 (https=)
MX (1) MXPA04006084A (https=)
NO (1) NO20042172L (https=)
PL (1) PL374949A1 (https=)
SK (1) SK2432004A3 (https=)
WO (1) WO2003053339A2 (https=)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
JP2007504215A (ja) 2003-09-03 2007-03-01 バイオフォームズ 生体分子を急速に結晶化するための方法及び装置
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
ES2779957T3 (es) * 2004-10-05 2020-08-20 Novo Nordisk As Preparación farmacéutica que contiene insulina en forma cristalina así como también solubilizada
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
CN101573133B (zh) * 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
US9150633B2 (en) * 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
JP5695909B2 (ja) * 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
MY152979A (en) * 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
EP2296692A4 (en) * 2008-04-22 2012-06-06 Univ Case Western Reserve ISOFORM-SPECIFIC INSULIN ANALOG
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
MX2011001181A (es) * 2008-07-31 2011-04-05 Univ Case Western Reserve Insulina estabilizada con halogeno.
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
AU2013237740B2 (en) * 2008-07-31 2016-06-02 Case Western Reserve University Insulin analogues containing penta-fluora-phenyalanine at position B24
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
WO2010080605A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
AU2009335715B2 (en) * 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376099A4 (en) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
CN102471368A (zh) * 2009-08-11 2012-05-23 拜康有限公司 色谱方法及其纯化的化合物
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
JP5119232B2 (ja) * 2009-11-06 2013-01-16 株式会社マルハニチロ食品 プロタミンの定量法
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2010327949A1 (en) * 2009-12-11 2012-06-28 Case Western Reserve University Insulin analogues with chlorinated amino acids
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EP2585102B1 (en) * 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
JP2014509603A (ja) * 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
DK2741765T3 (en) 2011-08-10 2016-06-13 Adocia Injectable solution of at least one type of basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
US9198971B2 (en) * 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
EP2804621A4 (en) * 2012-01-20 2015-11-18 Univ Case Western Reserve GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
IN2015DN00544A (https=) 2012-07-23 2015-06-26 Zealand Pharma As
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
FR3013049B1 (fr) * 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
BR112016015851A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
BR112017004544A2 (pt) 2014-10-06 2018-01-23 Univ Case Western Reserve insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
KR20180002062U (ko) 2016-12-28 2018-07-06 유애자 크리스탈이 구비된 조명커버
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
TW201938190A (zh) 2017-12-07 2019-10-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的ph 7之可注射溶液
IL275192B2 (en) 2017-12-07 2025-06-01 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3084585B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
WO2020115334A1 (fr) 2018-12-07 2020-06-11 Adocia Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020245470A1 (fr) 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
NZ245170A (en) * 1991-11-26 1994-07-26 Lilly Co Eli Insulin and proinsulin analogues with arg at b31, b32 and ao and pharmaceutical compositions
ATE203998T1 (de) * 1993-04-27 2001-08-15 Hoechst Ag Amorphe monosphärische formen von insulinderivaten
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5491269A (en) * 1994-09-15 1996-02-13 Exxon Production Research Company Method for inhibiting hydrate formation
US5491296A (en) * 1994-12-05 1996-02-13 Holden's Foundation Seeds, Inc. Inbred corn line LH176
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521006A (ja) * 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives

Also Published As

Publication number Publication date
CO5590884A2 (es) 2005-12-30
IL161848A0 (en) 2005-11-20
JP2005519041A (ja) 2005-06-30
EP1545460A2 (en) 2005-06-29
CA2468100A1 (en) 2003-07-03
WO2003053339A3 (en) 2005-04-14
PL374949A1 (en) 2005-11-14
SK2432004A3 (sk) 2005-04-01
NO20042172L (no) 2004-09-17
MXPA04006084A (es) 2005-03-31
HUP0700126A2 (en) 2007-06-28
WO2003053339A2 (en) 2003-07-03
EP1545460A4 (en) 2005-11-16
AU2002346490A1 (en) 2003-07-09
KR20040070237A (ko) 2004-08-06
US20050014679A1 (en) 2005-01-20
CZ2004710A3 (cs) 2005-02-16
HRP20040551A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
BR0215029A (pt) Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR0014767A (pt) Fibras de sementes de plantas e uso
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
BRPI0418702A (pt) composição para a liberação sustentada de polipetìdeo biologicamente ativo, método para tratar um paciente sofrendo de diabetes tipo 2, processo para preparar uma composição para a liberação sustentada de um polipeptìdeo, composição para a liberação sustentada de um agente biologicamente ativo, processo para preparar uma composição para a liberação sustentada de exendina-4, composição injetável, kit para produzir uma composição injetável, composição farmaceuticamente aceitável para a liberação sustentada de um polipeptìdeo biologicamente ativo e método para tratar um paciente sofrendo de diabetes mellitus
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
BRPI0111116B8 (pt) imitadores de trombopoietina
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
BRPI0409600A (pt) análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
EA200501592A1 (ru) Способы и композиции для введения агонистов trpv1
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0412971A (pt) método de alongamento do cabelo
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0609765B8 (pt) mistura de isoalcano, composição cosmética ou farmacêutica, composição cosmética de cabelo, método para a preparação de uma mistura de isoalcano, e, uso da mesma
BR0107902A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade
BR0316040A (pt) Composto, métodos para tratar doenças, para tratar edema macular, degeneração macular, aumentar a velocidade do sangue retinal e da cabeça do nervo óptico, aumentar a tensão de oxigênio retinal e do nervo óptico e/ou um efeito neuroprotetor, para prevenir a repolarização ou a hiperpolarização de uma célula de mamìfero contendo canal de potássio, e para tratar do diabete, e, composição
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
BR0205062A (pt) Spandex e processo para produzir spandex

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.